S-Space

Browse

Subject

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 37 of 37

Issue Date	Title / Author(s) / Citation	File
2006-11	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients Han, Sae-Won; Kim, Tae-You; Lee, Kyung-Hun; Hwang, Pil Gyu; Jeon, Yoon Kyung; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Chung, Doo Hyun; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.54 No.2, pp.201-207	DOI
2009-07	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI Yi, Hyeon Gyu; Kim, Hye Jin; Kim, Yu Jung; Han, Sae-Won; Oh, Do-Youn; Lee, Se-Hoon; Kim, Dong-Wan; Im, Seock-Ah; Kim, Tae-You; Kim, Chul Soo; Heo, Dae Seog; Bang, Yung-Jue Lung Cancer, Vol.65 No.1, pp.80-84	DOI
2011-04	EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma Koh, Youngil; Jang, Bogun; Jeon, Yoon Kyung; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Chung, Doo Hyun; Kim, Young Tae; Kim, Young Whan; Heo, Dae Seog Japanese Journal of Clinical Oncology, Vol.41 No.4, pp.548-554	DOI
2011-05	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification Ou, Sai-Hong Ignatius; Kwak, Eunice L.; Siwak-Tapp, Christina; Dy, Joni; Bergethon, Kristin; Clark, Jeffrey W.; Camidge, D. Ross; Solomon, Benjamin J.; Maki, Robert G.; Bang, Yung-Jue; Kim, Dong-Wan; Christensen, James; Tan, Weiwei; Wilner, Keith D.; Salgia, Ravi; Iafrate, A. John Journal of Thoracic Oncology, Vol.6 No.5, pp.942-946	DOI
2012-08	EGFR mutations as a predictive marker of cytotoxic chemotherapy Park, Jin Hyun; Lee, Se-Hoon; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Yang, Seok-Chul; Kim, Young Whan; Heo, Dae Seog Lung Cancer, Vol.77 No.2, pp.433-437	DOI
2013-08	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study Lee, J. K.; Shin, J. -Y.; Kim, S.; Lee, S.; Park, C.; Kim, J. -Y.; Koh, Y.; Keam, B.; Min, H. S.; Kim, T. M.; Jeon, Y. -K.; Kim, D. -W.; Chung, D. H.; Heo, D. S.; Lee, S. -H.; Kim, J. -I. Annals of Oncology, Vol.24 No.8, pp.2080-2087	DOI
2014-02	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC Ou, Sai-Hong I.; Jaenne, P. A.; Bartlett, C. H.; Tang, Y.; Kim, D. -W.; Otterson, G. A.; Crino, L.; Selaru, P.; Cohen, D. P.; Clark, J. W.; Riely, G. J. Annals of Oncology, Vol.25 No.2, pp.415-422	DOI
2014-09	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial Yang, James Chih-Hsin; Kang, Jin Hyoung; Mok, Tony; Ahn, Myung-Ju; Srimuninnimit, Vichien; Lin, Chia-Chi; Kim, Dong-Wan; Tsai, Chun-Ming; Barraclough, Helen; Altug, Sedat; Orlando, Mauro; Park, Keunchil European Journal of Cancer, Vol.50 No.13, pp.2219-2230	DOI
2014-10	Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Keam, Bhumsuk; Kim, Dong-Wan; Park, Jin Hyun; Lee, Jeong-Ok; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Cancer Research and Treatment, Vol.46 No.4, pp.323-330	view file DOI
2014-11	Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer Blackhall, Fiona; Kim, Dong-Wan; Besse, Benjamin; Nokihara, Hiroshi; Han, Ji-Youn; Wilner, Keith D.; Reisman, Arlene; Iyer, Shrividya; Hirsh, Vera; Shaw, Alice T. Journal of Thoracic Oncology, Vol.9 No.11, pp.1625-1633	DOI
2014-12	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial Jaenne, Pasi A.; Ou, Sai-Hong I.; Kim, Dong-Wan; Oxnard, Geoffrey R.; Martins, Renato; Kris, Mark G.; Dunphy, Frank; Nishio, Makoto; O'Connell, Joseph; Paweletz, Cloud; Taylor, Ian; Zhang, Hui; Goldberg, Zelanna; Mok, Tony The Lancet Oncology, Vol.15 No.13, pp.1433-1441	DOI
2014-12	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score Lee, Dae-Won; Shin, Dong-Yeop; Kim, Jin Wook; Keam, Bhumsuk; Kim, Tae Min; Kim, Hak Jae; Kim, Dong-Wan; Wu, Hong-Gyun; Paek, Sun Ha; Kim, Young Whan; Heo, Dae Seog; Kim, Dong Gyu; Lee, Se-Hoon Lung Cancer, Vol.86 No.3, pp.363-368	DOI
2015	Dihydroergotamine Tartrate Induces Lung Cancer Cell Death through Apoptosis and Mitophagy Chang, Seung-Hee; Lee, Ah Young; Yu, Kyeong-Nam; Park, Jongsun; Kim, Kwang Pyo; Cho, Myung-Haing Chemotherapy, Vol.61 No.6, pp.304-312	DOI
2015-04	The impact of molecularly targeted treatment on direct medical costs in patients with advanced non-small cell lung cancer Lee, June-Koo; Kim, Dong-Wan; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Young-Joo; Heo, Dae Seog Cancer Research and Treatment, Vol.47 No.2, pp.182-188	view file DOI
2015-04	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer Jaenne, Pasi A.; Yang, James Chih-Hsin; Kim, Dong-Wan; Planchard, David; Ohe, Yuichiro; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Su, Wu-Chou; Horn, Leora; Haggstrom, Daniel; Felip, Enriqueta; Kim, Joo-Hang; Frewer, Paul; Cantarini, Mireille; Brown, Kathryn H.; Dickinson, Paul A.; Ghiorghiu, Serban; Ranson, Malcolm New England Journal of Medicine, Vol.372 No.18, pp.1689-1699	DOI
2015-08	Total lesion glycolysis in positron emission tomography can predict gefitinib outcomes in non-small-cell lung cancer with activating EGFR mutation Keam, Bhumsuk; Lee, Soo Jin; Kim, Tae Min; Paeng, Jin Chul; Lee, Se-Hoon; Kim, Dong-Wan; Jeon, Yoon Kyung; Chung, Doo Hyun; Kang, Keon Wook; Chung, June-Key; Heo, Dae Seog Journal of Thoracic Oncology, Vol.10 No.8, pp.1189-1194	DOI
2015-10	Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations Park, Sehhoon; Keam, Bhumsuk; Kim, Se Hyun; Kim, Ki Hwan; Kim, Yu Jung; Kim, Jin-Soo; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Lee, Jong Seok; Heo, Dae Seog Cancer Research and Treatment, Vol.47 No.4, pp.630-637	view file DOI
2015-12	Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor Kim, Tae Min; Song, Ahnah; Kim, Dong-Wan; Kim, Soyeon; Ahn, Yong-Oon; Keam, Bhumsuk; Jeon, Yoon Kyung; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog Journal of Thoracic Oncology, Vol.10 No.12, pp.1736-1744	DOI
2016-02	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee, Ji Yun; Xu Qing; Wei Xiumin; Bai Yali; Chi, Sangah; Bak, So Hyeon; Lee, Ho Yun; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Cho, Eun Kyung; Kim, Dong-Wan; Kim, Hye Ryun; Min, Young Joo; Jung, Sin-Ho; Park, Keunchil; Mao Mao; Ahn, Myung-Ju Oncotarget, Vol.7 No.6, pp.6984-6993	view file DOI
2016-03	Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer Park, Sehhoon; Park, Seongyeol; Lee, Se-Hoon; Suh, Beomseok; Ock, Chan-Young; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog Cancer Biomarkers, Vol.16 No.3, pp.425-433	DOI
2016-03	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. Annals of Oncology, Vol.27 No.3, pp.417-423	DOI
2016-05	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Arvis Karl; Laurie, Scott A.; Tsai, Chun-Ming; Shahidi, Mehdi; Kim, Miyoung; Massey, Dan; Zazulina, Victoria; Paz-Ares, Luis The Lancet Oncology, Vol.17 No.5, pp.577-589	DOI
2016-10	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity Ballard, Peter; Yates, James W. T.; Yang, Zhenfan; Kim, Dong-Wan; Yang, James Chih-Hsin; Cantarini, Mireille; Pickup, Kathryn; Jordan, Angela; Hickey, Mike; Grist, Matthew; Box, Matthew; Johnstrom, Peter; Varnas, Katarina; Malmquist, Jonas; Thress, Kenneth S.; Janne, Pasi A.; Cross, Darren Clinical Cancer Research, Vol.22 No.20, pp.5130-5140	DOI
2017-02	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial Paz-Ares, L.; Tan, E. -H.; O'Byrne, K.; Zhang, L.; Hirsh, V.; Boyer, M.; Yang, J. C. -H.; Mok, T.; Lee, K. H.; Lu, S.; Shi, Y.; Lee, D. H.; Laskin, J.; Kim, D. -W.; Laurie, S. A.; Kolbeck, K.; Fan, J.; Dodd, N.; Marten, A.; Park, K. Annals of Oncology, Vol.28 No.2, pp.270-277	DOI
2017-04	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042) Kim, Dong-Wan; Garon, Edward B.; Jatoi, Aminah; Keefe, Dorothy M.; Lacouture, Mario E.; Sonis, Stephen; Gernhardt, Diana; Wang, Tao; Giri, Nagdeep; Doherty, Jim P.; Nadanaciva, Sashi; O'Connell, Joseph; Sbar, Eric; Cho, Byoung Chul Lung Cancer, Vol.106, pp.76-82	DOI
2017-05	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer Park, Sehhoon; Kim, Ji-Yeon; Lee, Se-Hoon; Suh, Beomseok; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.32 No.3, pp.514-522	view file DOI
2017-11	The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors Kim, Hyungjin; Park, Chang Min; Keam, Bhumsuk; Park, Sang Joon; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Goo, Jin Mo PLoS ONE, Vol.12 No.11, p. e0187500	view file DOI
2018-03	Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer Ramalingam, Suresh S.; Yang, James C. -H.; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Mann, Helen; Rukazenkov, Yuri; Ghiorghiu, Serban; Stetson, Daniel; Markovets, Aleksandra; Barrett, J. Carl; Thress, Kenneth S.; Janne, Pasi A. Journal of Clinical Oncology, Vol.36 No.9, pp.841-849	DOI
2018-11	Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer Wu, Yi-Long; Zhang, Li; Kim, Dong-Wan; Liu, Xiaoqing; Lee, Dae Ho; Yang, James Chih-Hsin; Ahn, Myung-Ju; Vansteenkiste, Johan F.; Su, Wu-Chou; Felip, Enriqueta; Chia, Vincent; Glaser, Sabine; Pultar, Philippe; Zhao, Sylvia; Peng, Bin; Akimov, Mikhail; Tan, Daniel S. W. Journal of Clinical Oncology, Vol.36 No.31, pp.3101-3109	DOI
2019-01	The risk of herpes zoster in patients with non-small cell lung cancer according to chemotherapy regimens: Tyrosine kinase inhibitors versus cytotoxic chemotherapy Choi, Ji Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Jo, Seong Jin Cancer Research and Treatment, Vol.51 No.1, pp.169-177	view file DOI
2019-06	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression Schuler, Martin; Tan, Eng-Huat; O'Byrne, Kenneth; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai; Kim, Sang-We; Laskin, Janessa; Kim, Dong-Wan; Arvis, Catherine Dubos; Kolbeck, Karl; Massey, Dan; Maerten, Angela; Paz-Ares, Luis; Park, Keunchil Journal of Cancer Research and Clinical Oncology, Vol.145 No.6, pp.1569-1579	DOI
2019-09	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial Kim, Dong-Wan; Lee, Dae Ho; Han, Ji-Youn; Lee, Jongseok; Cho, Byoung Chul; Kang, Jin Hyoung; Lee, Ki Hyeong; Cho, Eun Kyung; Kim, Jin-Soo; Min, Young Joo; Cho, Jae Yong; An, Ho Jung; Kim, Hoon-Gu; Lee, Kyung Hee; Kim, Bong-Seog; Jang, In-Jin; Yoon, Seonghae; Han, OakPil; Noh, Young Su; Hong, Ka Young; Park, Keunchil Lung Cancer, Vol.135, pp.66-72	DOI
2019-09	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer Ock, Chan-Young; Yoo, Shin-Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong Wan; Chung, Doo Hyun; Heo, Dae Seog The Korean Journal of Internal Medicine, Vol.34 No.5, pp.1116-1124	view file DOI
2020-02	Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study Yang, James C. H.; Kim, Sang-We; Kim, Dong-Wan; Lee, Jong-Seok; Cho, Byoung Chul; Ahn, Jin-Seok; Lee, Dae H.; Kim, Tae Min; Goldman, Jonathan W.; Natale, Ronald B.; Brown, Andrew P.; Collins, Barbara; Chmielecki, Juliann; Vishwanathan, Karthick; Mendoza-Naranjo, Ariadna; Ahn, Myung-Ju Journal of Clinical Oncology, Vol.38 No.6, pp.538-547	DOI
2021-05	Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study Park, Keunchil; Janne, Pasi A.; Kim, Dong-Wan; Han, Ji-Youn; Wu, Ming-Fang; Lee, Jong-Seok; Kang, Jin-Hyoung; Lee, Dae Ho; Cho, Byoung Chul; Yu, Chong-Jen; Pang, Yong Kek; Felip, Enriqueta; Kim, Hyunjin; Baek, Eunhye; Noh, Young Su Cancer, Vol.127 No.9, pp.1407-1416	DOI
2022-01	Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer Lee, Chaelin; Kim, Miso; Kim, Dong-Wan; Kim, Tae Min; Kim, Soyeon; Im, Sun-Wha; Jeon, Yoon Kyung; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog Cancer Research and Treatment, Vol.54 No.1, pp.140-149	DOI
2023-08	BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer Lim, Sun Min; Fujino, Toshio; Kim, Chulwon; Lee, Gwanghee; Lee, Yong-Hee; Kim, Dong-Wan; Ahn, Jin Seok; Mitsudomi, Tetsuya; Jin, Taiguang; Lee, Sang-Yoon Clinical Cancer Research, Vol.29 No.16, pp.3004-3016	DOI